Advertisement
Screener

COSCIENS Biopharma Inc. (CSCIF) Income Tax Expense Continuing Operations

2.8 / 5 stars · 68/120 Roast Me

COSCIENS Biopharma Inc. Income Tax Expense Continuing Operations

COSCIENS Biopharma Inc. (CSCIF) reported Income Tax Expense Continuing Operations of $10.00 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.

Financial Statements › Expense Statement

ifrs-full:IncomeTaxExpenseContinuingOperations · last filed 2026-03-25

  • COSCIENS Biopharma Inc. income tax expense continuing operations for the quarter ending 2025-06-30 was $1.00K.
  • COSCIENS Biopharma Inc. income tax expense continuing operations for the quarter ending 2024-12-31 was $1.08M.
  • COSCIENS Biopharma Inc. income tax expense continuing operations for the quarter ending 2024-09-30 was -$112.00K.
  • COSCIENS Biopharma Inc. income tax expense continuing operations for the quarter ending 2024-06-30 was -$474.00K.
Period endIncome Tax Expense Continuing Operations 3 monthIncome Tax Expense Continuing Operations 6 monthIncome Tax Expense Continuing Operations 9 monthIncome Tax Expense Continuing Operations 12 month
2025-12-31$10.00K
20-F · filed 2026-03-25
2025-06-30$1.00K
6-K · filed 2025-08-14
$1.00K
6-K · filed 2025-08-14
2024-12-31$1.08M
derived: 20-F 12 month − 6-K 9 month · filed 2026-03-25
$970.00K
derived: sum of 2 quarters · filed 2026-03-25
$496.00K
derived: sum of 3 quarters · filed 2026-03-25
$84.00K
20-F · filed 2026-03-25
2024-09-30-$112.00K
6-K · filed 2025-11-12
-$586.00K
derived: sum of 2 quarters · filed 2025-11-12
-$998.00K
6-K · filed 2025-11-12
-$1.36M
derived: sum of 4 quarters · filed 2026-03-25
2024-06-30-$474.00K
6-K · filed 2025-08-14
-$886.00K
6-K · filed 2025-08-14
-$1.25M
derived: sum of 3 quarters · filed 2026-03-25
-$1.46M
derived: sum of 4 quarters · filed 2026-03-25
2024-03-31-$412.00K
6-K · filed 2025-05-13
-$772.00K
derived: sum of 2 quarters · filed 2026-03-25
-$984.00K
derived: sum of 3 quarters · filed 2026-03-25
-$1.22M
derived: sum of 4 quarters · filed 2026-03-25
2023-12-31-$360.00K
derived: 20-F 12 month − 6-K 9 month · filed 2026-03-25
-$572.00K
derived: sum of 2 quarters · filed 2026-03-25
-$807.00K
derived: sum of 3 quarters · filed 2026-03-25
-$885.00K
20-F · filed 2026-03-25
2023-09-30-$212.00K
6-K · filed 2024-11-12
-$447.00K
derived: sum of 2 quarters · filed 2024-11-12
-$525.00K
6-K · filed 2024-11-12
2023-06-30-$235.00K
6-K · filed 2024-08-13
-$313.00K
6-K · filed 2024-08-13
2022-12-31$1.08M
20-F · filed 2025-04-09
2021-12-31$20.00K
derived: 20-F/A 12 month − 6-K 9 month · filed 2024-07-17
$20.00K
derived: sum of 2 quarters · filed 2024-07-17
$20.00K
derived: sum of 3 quarters · filed 2024-07-17
-$109.00K
20-F/A · filed 2024-07-17
2021-09-30$0.00
derived: 6-K 9 month − 6-K/A 6 month · filed 2022-11-03
$0.00
derived: sum of 2 quarters · filed 2022-11-03
-$129.00K
6-K · filed 2022-11-03
2021-06-30$0.00
derived: 6-K/A 6 month − 6-K 3 month · filed 2022-08-04
-$129.00K
6-K/A · filed 2022-08-04
2021-03-31-$129.00K
6-K · filed 2022-05-11
2020-12-31$395.00K
20-F/A · filed 2024-02-15
2019-12-31-$188.00K
20-F · filed 2022-03-29
2018-12-31-$636.00K
derived: 20-F 12 month − 6-K 9 month · filed 2020-03-31
-$1.18M
derived: sum of 2 quarters · filed 2020-03-31
-$1.42M
derived: sum of 3 quarters · filed 2020-03-31
$5.45M
20-F · filed 2020-03-31
2018-09-30-$547.00K
6-K · filed 2019-11-07
-$780.00K
derived: sum of 2 quarters · filed 2019-11-07
$6.09M
6-K · filed 2019-11-07
2018-06-30-$233.00K
6-K · filed 2019-08-13
$6.63M
6-K · filed 2019-08-13
2017-12-31-$3.48M
20-F · filed 2020-03-31
2016-12-31$0.00
20-F · filed 2019-04-01
2015-12-31$0.00
20-F · filed 2018-03-28